NASDAQ:DRTX (DRTX) (DRTX) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free DRTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (DRTX) alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About (DRTX) Stock (NASDAQ:DRTX)Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. DRTX Stock News HeadlinesApril 17, 2024 | morningstar.comSynlait Milk Ltd SMLMarch 29, 2024 | nasdaq.comFSLR Crosses Above Key Moving Average LevelApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.November 16, 2023 | msn.comAttorney and parent speak on Disability Rights Texas' filed complaint on ECISDNovember 15, 2023 | msn.comECISD responds to Disability Rights complaintOctober 12, 2023 | msn.comHISD teachers accuse district of prohibiting disability accommodations for studentsJuly 14, 2023 | msn.comStorm Clouds: Shanahan Almost Hired by Rams?July 5, 2023 | msn.comWhen Raj Kapoor revealed why he never married Nargis, said that he ‘drew a line’ from day one and wife Krishna Raj ‘undersood’: ‘Nobody cheated anybody’April 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.July 5, 2023 | msn.comUAE: Discounts announced for zip line, Jebel Jais sledder experiences; adventure park to remain open throughout summerApril 8, 2023 | msn.comUFC 287 Loses Bout In Final HourMarch 15, 2023 | msn.comEddie Nketiah and Folarin Balogun both face summer Arsenal exit question after £27m transferFebruary 25, 2023 | msn.comDisability rights group calls on state to address Austin ISD's ongoing delayed evaluationsFebruary 7, 2023 | msn.comSt. Andrews to leave the 700-year-old Swilcan Bridge aloneJanuary 23, 2023 | msn.comCampus notesJanuary 12, 2023 | msn.comUK Prime Minister Comes Under Fire For 30 Minute Private Jet Flight To LeedsJanuary 11, 2023 | msn.comMore than half of people in Cambridge have higher education qualificationNovember 2, 2022 | msn.comAlec Bohm has progressed from hater to hitter, turning early-season boos to cheersOctober 21, 2022 | msn.comTrump ally Steve Bannon faces sentencing for contemptAugust 14, 2022 | msn.comAamir Khan joins PM Modi’s ‘Har Ghar Tiranga’ campaign, displays flag at his houseAugust 2, 2022 | msn.comWatch: Messi stops security from dragging young fan away as he struggles to take selfie with PSG starMarch 2, 2022 | msn.comTarrant County voters share their experiences, issues faced during primary electionNovember 11, 2021 | msn.comJudge knocks down Abbott's ban on mask mandates in Texas schoolsSee More Headlines Receive DRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (DRTX) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:DRTX CUSIP26658A10 CIK1544116 WebN/A Phone+1-312-2197000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report DRTX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of (DRTX) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (DRTX) investors own include Allena Pharmaceuticals (ALNA), Arbutus Biopharma (ABUS), AcelRx Pharmaceuticals (ACRX), Ampliphi Biosciences (APHB), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Five Prime Therapeutics (FPRX), Glu Mobile (GLUU) and Inovio Pharmaceuticals (INO). This page (NASDAQ:DRTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (DRTX) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
